（来源：中国宁波网） 转自：中国宁波网 为贯彻落实《"健康中国2030"规划纲要》《加速消除宫颈癌行动计划（2023-2030年）》等文件精神， 深入推进疫苗相关疾病防控，提高人民群众健康水平，浙江省多地推进适龄人群HPV疫苗惠民接种活 动，为适龄男女构筑起更加坚实的健康防护屏障。 基础有保障，选择有优惠，早预防早保护 2025年，浙江多地陆续推出HPV疫苗惠民接种活动。其中，9-26岁、35-45岁女性及16-26岁男性接种进 口九价HPV疫苗，可享受最后一剂次疫苗费用减免；多个地区还将带状疱疹疫苗纳入惠民范围。 浙江省的HPV疫苗惠民接种活动社会反响良好，考虑到群众仍有接种意愿，为最大程度满足适龄人群接 种需求，多地已决定延长项目接种周期。有意参加进口九价HPV疫苗惠民活动的适龄人群需注意，在杭 州市、宁波市、温州市、湖州市、嘉兴市、绍兴市、金华市、衢州市、舟山市、台州市、丽水市等大部 分地市，首剂接种截止时间为2026年9月30日，并于2027年3月31日前在同一门诊完成全程接种方可享受 优惠。特别提醒的是，因各区县惠民活动起止时间不一致，具体以当地出台政策为准，适龄人群可向就 近社区卫生服务中心或乡镇 ...

中国女性约98%的宫颈癌由高危型HPV导致，接种HPV疫苗是预防HPV感染及相关疾病的重要措施。记 者了解到，珠海近期推出了"打一免一"HPV疫苗预防接种惠民活动，形成独特的"国家免费基础保障+地 方惠民升级选择"双轨并行模式。符合条件的市民于活动期间接种首针，可享受第二剂或第三剂费用减 免优惠。 "昨天社区通知了我，今天我就带着女儿过来接种了，也是希望孩子能够得到保护。"12月21日上午，在 珠海市香洲区梅华社区健康服务中心，前来带孩子接种HPV疫苗的居民黄女士如是说道。 对此，基层机构变"被动等"为"主动送"。据悉，梅华社区健康服务中心开设周末接种专场，提供从咨 询、登记到接种、留观的一站式服务；主动与学校和社区联动，通过专用预约链接或二维码简化预约流 程，并开设专属咨询热线答疑解惑。 "双轨模式"赋予家庭选择权与主动权 9-14周岁女性可享受第2剂免费 12月21日上午9时许，梅华社区健康服务中心接种门诊大厅内人头攒动，已有不少居民前来登记、接种 疫苗。记者在现场看到，大厅出入口与前台均摆放了介绍疫苗接种惠民活动的宣传资料，居民们在等候 区有序等候接种。 据介绍，国家疾控局、国家卫生健康委、教育部等七部 ...

Core Insights - The article emphasizes the high prevalence of HPV infection among men in China and the importance of early prevention strategies [2][4][8] - It highlights the recent approval of HPV vaccines for males, marking a new era in immunization against HPV-related diseases [3][6] - The need for increased public awareness and education regarding male HPV vaccination is underscored, as many men are unaware of their susceptibility to HPV [4][5][7] Summary by Sections - **HPV Infection in Men** - High infection rates among men in China, with peaks in young and middle-aged groups [2] - HPV can lead to various cancers in men, including anal, penile, and oropharyngeal cancers, with increasing incidence rates [2][4] - **Vaccination Initiatives** - Two HPV vaccines are available for males: a four-valent vaccine for ages 9-26 and a nine-valent vaccine for ages 16-26 [3] - The introduction of male vaccination is part of a broader strategy to combat HPV-related diseases [3][6] - **Public Awareness and Education** - There is a significant gap in public knowledge regarding male HPV infection and vaccination [4] - Efforts are needed to dispel myths and promote the concept of "co-prevention" for both genders [4][5] - **International Practices and Recommendations** - Global evidence supports the inclusion of male vaccination in national immunization programs to reduce HPV transmission and related diseases [6][7] - Successful examples from countries like Australia demonstrate the effectiveness of gender-inclusive vaccination strategies [7] - **Strategic Recommendations** - Six major initiatives proposed for male HPV prevention include comprehensive strategies, enhanced health education, and innovative funding mechanisms [8][9] - Collaboration across departments and leveraging technology for data-driven decision-making are essential for effective implementation [9]

Core Insights - The article discusses the implementation of HPV vaccination initiatives in various regions of Jiangsu Province, aimed at increasing vaccination coverage and protecting public health [1][2][3] Group 1: Vaccination Initiatives - The HPV vaccination initiative targets diverse demographics, including females aged 9-26 and 35-45, and males aged 16-26, with a fee waiver for the last dose of the imported nine-valent HPV vaccine [1][2] - The program is not limited by residency status but has a time constraint, requiring the first dose to be administered by November 30, 2025, and all three doses completed by June 30, 2026, to qualify for the discount [1][2] Group 2: Health Implications of HPV - HPV is linked to various cancers, with 99.7% of cervical cancer cases associated with high-risk HPV types, emphasizing the importance of vaccination for both genders [2][3] - Early vaccination during the peak infection window is crucial for effective immune response, providing lifelong benefits and reducing the risk of related diseases [3][4] Group 3: Vaccine Safety and Efficacy - The imported nine-valent HPV vaccine has been proven safe and effective, with over 10 years of protection demonstrated in real-world studies across 112 countries since its launch in 2014 [4] - The nine-valent vaccine covers nine HPV types, including those most commonly associated with cervical cancer in Chinese women, enhancing its preventive capabilities [4] Group 4: Community Engagement and Accessibility - The vaccination program is actively promoted in multiple cities within Jiangsu, with local health institutions encouraging residents to consult and schedule vaccinations [5] - The initiative aims to foster gender-inclusive health protection, with various regions implementing similar time-limited vaccination campaigns to broaden access [5]

Core Viewpoint - The article discusses the implementation of a special HPV vaccine policy in Shenyang's Tiexi District, aimed at promoting public health and preventing HPV-related diseases among both males and females, reflecting a shift towards a more inclusive approach to HPV prevention [1][2]. Group 1: HPV Vaccine Policy - The policy covers females aged 9-45 and males aged 9-26, establishing a comprehensive HPV prevention network that includes targeted protection for youth and ongoing coverage for adult women [1] - Eligible individuals can receive free doses of the HPV vaccine: for the imported quadrivalent vaccine, females aged 9-13 receive the second dose for free, while females aged 14-26, 35-45, and males aged 9-26 receive the third dose for free [1] - The imported nine-valent HPV vaccine offers similar benefits, with free second doses for females aged 9-14 and free third doses for females aged 15-26, 35-45, and males aged 16-26 [1] Group 2: Public Health Impact - The initiative aims to block the HPV transmission chain and reduce the risk of related diseases such as anal and penile cancers in males, marking a transition from a single-gender cervical cancer prevention strategy to a more comprehensive approach [2] - The nine-valent HPV vaccine is the first and only approved vaccine in China that can prevent cancers and diseases caused by persistent HPV infections in both males and females [2] Group 3: Participation and Timeline - The program is open to all eligible individuals regardless of residency, encouraging widespread participation in the health initiative [2] - The vaccination campaign has a time window, with the first dose discount available until November 30, 2025, and individuals must complete their vaccination by May 31, 2026, to benefit from the discounts [2]

Group 1 - The core point of the news is that Wantai Biological's nine-valent HPV vaccine has received approval for market release in China, making it the first domestically produced nine-valent HPV vaccine approved for sale in the country [1] - The approval is expected to enhance the company's product lineup, creating new revenue and profit growth opportunities, and strengthening its market position [1] - The nine-valent HPV vaccine will complement the existing bivalent HPV vaccine, forming a competitive product matrix to meet diverse consumer needs [1] Group 2 - The domestically produced nine-valent HPV vaccine utilizes a novel E. coli expression system, offering advantages such as good immunogenicity, rapid growth, short production cycles, high yield, low cost, and scalability [2] - Clinical studies show that the domestic nine-valent HPV vaccine has comparable immunogenicity and safety to imported versions, with a 100% seroconversion rate for all nine HPV types and similar adverse reaction rates [2] - The vaccine is priced at 499 yuan per dose, approximately 40% lower than imported nine-valent HPV vaccines, making it more accessible [2] Group 3 - The rapid development of domestic HPV vaccines is supported by national policies, including the "Cervical Cancer Elimination Action Plan (2023-2030)" aimed at promoting HPV vaccination [2] - There is significant potential for increasing the overall vaccination rate in the domestic population, as awareness of HPV vaccination is gradually improving [2] - Multiple domestic companies, including Bowe Biotechnology, Kangla Health, Ruike Biotechnology, and Watson Bio, are advancing their nine-valent HPV vaccine development, with several already in phase III clinical trials [3] Group 4 - The Chinese HPV vaccine market is projected to expand significantly, potentially reaching a scale of 62.54 billion yuan by 2031, driven by the completion of clinical trials and increased vaccination awareness [3] - New technological approaches, such as mRNA vaccines, are being explored for HPV vaccination, with several companies already in clinical stages of developing domestic mRNA HPV vaccines [3]

Group 1 - The first domestically produced nine-valent HPV vaccine in China has been approved, marking it as the second in the world [1] - A head-to-head study published in The Lancet Infectious Diseases indicates that the domestic nine-valent HPV vaccine has comparable efficacy and safety to the imported version [1][16] - The anticipated price for the domestic vaccine is around 700-800 yuan per dose, significantly lower than the imported vaccine priced at approximately 1300 yuan per dose [1] Group 2 - The study involved 488 healthy women aged 18-26, who were randomly assigned to receive either the domestic or imported vaccine, with a 100% seroconversion rate observed in both groups [16][17] - The domestic vaccine, developed using a novel E. coli expression system, offers advantages such as shorter production cycles and lower costs, making it more accessible for eligible women in China [17]

Core Viewpoint - The launch of China's first domestically produced nine-valent HPV vaccine "Xinkening®9" at a price of 499 yuan per dose significantly undercuts the imported vaccine priced at 1300 yuan, marking the end of the "high-price era" for HPV vaccines [1] Group 1: Product Pricing and Market Impact - The domestic nine-valent HPV vaccine is priced at approximately 40% of the imported vaccine's market standard price [1] - The competitive pricing is expected to enhance the willingness of eligible women to get vaccinated, contributing to the establishment of a national immunity barrier and accelerating the goal of cervical cancer elimination [1] - The pricing strategy is projected to benefit over 100 million women in China and positively impact global cervical cancer prevention efforts [1] Group 2: Company Initiatives and Global Expansion - After the approval of the nine-valent HPV vaccine, the company is actively advancing the national bidding and procurement process as per its established plan [1] - The company is also working diligently on the WHOPQ certification process for the nine-valent HPV vaccine, leveraging its international achievements with the two-valent HPV vaccine, which has gained market access in over 20 countries and is included in the immunization programs of 8 countries [1] - The company expresses confidence in accelerating the overseas access and expansion of the nine-valent HPV vaccine through its established global network [1]

Group 1 - The Israeli government claims to have destroyed Iranian uranium enrichment facilities and will continue its operations to eliminate Iran's ballistic missile capabilities [3] - The Chinese government is organizing the evacuation of its citizens from Iran and Israel due to escalating military conflicts [4] - The State Council of China is actively promoting artificial intelligence to lead the transformation of research paradigms in state-owned enterprises [6] Group 2 - The Summer Davos Forum will be held in Tianjin from June 24 to 26, focusing on "Entrepreneurial Spirit in the New Era" and attracting over 1,700 representatives from more than 90 countries [7] - The new train operation schedule in China will be implemented on July 1, increasing the number of scheduled passenger trains by 236 to a total of 13,302 [8] - The Shanghai Municipal Bureau of Statistics reported a 4.8% year-on-year increase in industrial output value for large-scale industrial enterprises from January to May [13] Group 3 - The World Gold Council reported that 95% of surveyed central banks expect to continue increasing their gold reserves in the next 12 months, the highest percentage since the survey began in 2019 [15] - The U.S. Senate passed the "Genius Act," establishing a regulatory framework for stablecoins, marking a significant step in cryptocurrency legislation [17] - The European Commission proposed a legislative plan to phase out imports of Russian oil and gas by the end of 2027 [19]

Core Viewpoint - The article discusses the recent price reductions for imported HPV vaccines and shingles vaccines in China, highlighting various promotional campaigns aimed at increasing vaccination rates among different demographics [1][2]. Group 1: Vaccine Price Reductions - Several vaccination sites have launched promotional programs for imported HPV vaccines, including a "buy one, get one free" offer for the two-dose regimen for girls aged 9 to 14 [1]. - For women aged 15 to 45, the two-dose HPV vaccines are offered at significant discounts, with the two-dose regimen for the bivalent HPV vaccine costing only one dose, and the nine-valent vaccine costing two doses for three [1]. - The price per dose for the imported bivalent HPV vaccine is 588 yuan, while the nine-valent vaccine is priced at 1306 yuan, leading to substantial cost reductions for full vaccination [1]. Group 2: Broader Vaccine Promotions - In Dezhou, Shandong Province, promotional activities for imported four-valent and nine-valent HPV vaccines have been introduced, including free third doses for males aged 16 to 26 [2]. - The Jining Health Service Center has also initiated a discount for the imported shingles vaccine, reducing the price from 3260 yuan for two doses to 1652 yuan, a reduction of 1608 yuan [2]. Group 3: Industry Performance Challenges - Despite the price reductions, the performance of vaccine manufacturers has been disappointing, with significant declines in sales for core products like HPV vaccines [3]. - Zhifei Biological Products Co., Ltd. reported a 50.74% decrease in revenue to 26.07 billion yuan in 2024, and a 74.99% drop in net profit to 2.018 billion yuan [4]. - In Q1 2025, the company experienced a 79.16% decline in revenue compared to the previous year, resulting in a net loss of 305 million yuan [4]. Group 4: Company Strategies - The company aims to address operational challenges by focusing on inventory reduction, debt recovery, and lowering liabilities as part of its 2025 strategy [5]. - Efforts include optimizing sales policies, participating in local health promotion projects, and enhancing awareness of HPV vaccination for males [5]. - As of Q1 2025, the company's accounts receivable decreased to 14.6 billion yuan, indicating a focus on managing financial risks [5].